Atherosclerotic and thrombotic genetic and environmental determinants in Egyptian coronary artery disease patients: a pilot study | springermedicine.com

Springer Medicine

Top

BMC Cardiovascular Disorders

Published in:

Open Access 01-12-2017 | Research article

Atherosclerotic and thrombotic genetic and environmental determinants in Egyptian coronary artery disease patients: a pilot study

Authors: Manal S. Fawzy, Eman A. Toraih, Nagwa M. Aly, Abeer Fakhr-Eldeen, Dahlia I. Badran, Mohammad H. Hussein

Published in: BMC Cardiovascular Disorders | Issue 1/2017

Login to get access

Abstract

Background

Coronary artery disease (CAD) is the leading cause of morbidity and mortality worldwide. Multiple genetic variants in combination with various environmental risk factors have been implicated. This study aimed to investigate the association of twelve thrombotic and atherosclerotic gene variants in combination with other environmental risk factors with CAD risk in a preliminary sample of Egyptian CAD patients.

Methods

Twenty three consecutive CAD patients undergoing diagnostic coronary angiography and 34 unrelated controls, have been enrolled in the study. Genotyping was based on polymerase chain reaction and reverse multiplex hybridization. Five genetic association models were tested. Data distribution and variance homogeneity have been checked by Shapiro-Wilk test and Levene test, respectively; then the appropriate comparison test was applied. Spearman’s rank correlation coefficient was used for correlation analysis and logistic regression has been performed to adjust for significant risk factors. Clustering the study participants according to gene-gene and gene-environment interaction has been done by Detrended Correspondence Analysis (DCA).

Results

The univariate analysis indicated that the five variants; rs1800595 (FVR2; factor 5), rs1801133 (MTHFR; 5,10-methylenetetrahydrofolate reductase), rs5918 (HPA-1; human platelet antigen 1), rs1799752 (ACE; angiotensin-converting enzyme), and rs7412 and rs429358 (ApoE; apolipoprotein E) were significantly associated with CAD susceptibility under different genetic models. Multivariate analysis revealed clustering of the study population into three patient groups (P) and one control group. FVR2 was the most variant associated with CAD patients, combined with the factor V Leiden (FVL) variant in P1 cluster and with both ACE and MTHFR 667C > T in P2. Whereas, P3 was mostly affected by both MTHFR 667C > T and FXIII (factor 13) V89L mutations. When combined with traditional risk factors, P1 was mostly affected by dyslipidemia, smoking and hypertension, while P2 was mostly affected by their fasting blood sugar levels and ApoE variant.

Conclusions

Taken together, these preliminary results could have predictive value to be applied in refining a risk profile for our CAD patients, in order to implement early preventive interventions including specific antithrombotic therapy. Further large scale and follow-up studies are highly recommended to confirm the study findings.

Available only for authorised users

1.

Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Executive summary: heart disease and stroke statistics-2014 update: a report from the American heart association. Circulation. 2014;129:399–410.PubMedCrossRef

2.

Seef S, Jeppsson A, Stafström M. What is killing? People’s knowledge about coronary heart disease, attitude towards prevention and main risk reduction barriers in Ismailia, Egypt (descriptive cross-sectional study). Pan Afr Med J. 2013;15:137.PubMedPubMedCentral

3.

Almahmeed W, Arnaout MS, Chettaoui R, Ibrahim M, Kurdi MI, Taher MA, et al. Coronary artery disease in Africa and the Middle East. Ther Clin Risk Manag. 2012;8:65–72.PubMedPubMedCentralCrossRef

4.

Liu L, Li Y, Tollefsbol TO. Gene-environment interactions and epigenetic basis of human diseases. Curr Issues Mol Biol. 2008;10:25–36.PubMedPubMedCentral

5.

Raposo M, Sousa P, Nemeth S, Couto A, Santos M, Pinheiro J, et al. Polymorphism in cardiovascular diseases (CVD) susceptibility loci in the azores islands (Portugal). Open J Genet. 2011;1:48–53.CrossRef

6.

Roy H, Bhardwaj S, Yla-Herttuala S. Molecular genetics of atherosclerosis. Hum Genet. 2009;125:467–91.PubMedCrossRef

7.

Bustamante CD, Burchard EG, De la Vega FM. Genomics for the world. Nature. 2011;475:163–5.PubMedPubMedCentralCrossRef

8.

Himabindu G, Rajasekhar D, Latheef K, Sarma PVGK, Vanajakshamma V, Chaudhury A, et al. Factor V Leiden mutation is not a predisposing factor for acute coronary syndromes. Indian Heart J. 2012;64:570–5.PubMedPubMedCentralCrossRef

9.

Campo G, Pavasini R, Pollina A, Tebaldi M, Ferrari R. Coagulation factors and recurrence of ischemic and bleeding adverse events in patients with acute coronary syndromes. Thromb Res. 2013;132:151–7.PubMedCrossRef

10.

Kujovich JL. Factor V Leiden thrombophilia. Genet Med. 2011;13:1–16.PubMedCrossRef

11.

Burzotta F, Leone AM, Paciaroni K, De Stefano V, Rossi E, Testa L, et al. G20210A prothrombin gene variant and clinical outcome in patients with a first acute coronary syndrome. Haematologica. 2004;89:1134–8.PubMed

12.

Ye Z, Liu EH, Higgins JP, Keavney BD, Lowe GD, Collins R, et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and controls. Lancet. 2006;367:651–8.PubMedCrossRef

13.

Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698–703.PubMed

14.

Kobbervig C, Williams E. FXIII polymorphisms, fibrin clot structure and thrombotic risk. Biophys Chem. 2004;112:223–8.PubMedCrossRef

15.

Gemmati D, Serino ML, Ongaro A, Tognazzo S, Moratelli S, Resca R, et al. A common mutation in the gene for coagulation factor XIII-A (VAL34Leu): a risk factor for primary intracerebral hemorrhage is protective against atherothrombotic diseases. Am J Hematol. 2001;67:183–8.PubMedCrossRef

16.

Isotalo PA, Wells GA, Donnelly JG. Neonatal and fetal methylenetetrahydrofolate reductase genetic polymorphisms: an examination of C677T and A1298C mutations. Am J Hum Genet. 2000;67:986–90.PubMedPubMedCentralCrossRef

17.

Zetterberg H, Regland B, Palmer M, Ricksten A, Palmqvist L, Rymo L, et al. Increased frequency of combined methylenetetrahydrofolate reductase C677T and A1298C mutated alleles in spontaneously aborted embryos. Eur J Hum Genet. 2002;10:113–8.PubMedCrossRef

18.

Hoekstra T, Geleijnse JM, Schouten EG, Kluft C. Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular risk. Thromb Haemost. 2004;91:861–72.PubMed

19.

Ndrepepa G, Braun S, King L, Fusaro M, Keta D, Cassese S, et al. Relation of fibrinogen level with cardiovascular events in patients with coronary artery disease. Am J Cardiol. 2013;111:804–10.PubMedCrossRef

20.

Boekholdt SM, Bijsterveld NR, Moons AH, Levi M, Buller HR, Peters RJ. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction: a systematic review. Circulation. 2001;104:3063–8.PubMedCrossRef

21.

Jood K, Ladenvall P, Tjarnlund-Wolf A, Ladenvall C, Andersson M, Nilsson S, et al. Fibrinolytic gene polymorphism and ischemic stroke. Stroke. 2005;36:2077–81.PubMedCrossRef

22.

Rallidis LS, Gialeraki A, Fountoulaki K, Politou M, Sourides V, Travlou A, et al. G-455A polymorphism of beta-fibrinogen gene and the risk of premature myocardial infarction in Greece. Thromb Res. 2010;125:34–7.PubMedCrossRef

23.

Ghosh K, Kulkarni B, Nair S, Shetty S, Mohanty D. Human platelet alloantigen polymorphism in Glanzmann’sthrombasthenia and its impact on the severity of the disease. Br J Haematol. 2002;119:348–53.PubMedCrossRef

24.

Loncar R, Stoldt V, Hellmig S, Zotz RB, Mihalj M, Scharf RE. HPA-1 polymorphism of αIIbβ3 modulates platelet adhesion onto immobilized fibrinogen in an in-vitro flow system. Thromb J. 2007;5:2.PubMedPubMedCentralCrossRef

25.

Kutluturk I, Karagöz A, Bezgin T, Oduncu V, Elveran A, Doğan C, et al. Relationship between angiotensin I-converting enzyme insertion/deletion gene polymorphism and retinal vein occlusion. Thromb J. 2014;12:17.PubMedPubMedCentralCrossRef

26.

Farrokhi E, Shayesteh F, Asadi Mobarakeh S, Roghani Dehkordi F, Ghatreh Samani K, Hashemzadeh CM. Molecular characterization of Iranian patients with possible familial hypercholesterolemia. Indian J Clin Biochem. 2011;26:244–8.PubMedPubMedCentralCrossRef

27.

Zhang M-d G, Gu W, Qiao S-b, Zhu E-j, Zhao Q-m, Lv SZ. Apolipoprotein E gene polymorphism and risk for coronary heart disease in the Chinese population: a meta-analysis of 61 studies including 6634 cases and 6393 controls. PLoS One. 2014;9:e95463.PubMedPubMedCentralCrossRef

28.

Kamal HM, Ahmed AS, Fawzy MS, Mohamed FA, Elbaz AA. Plasma thrombin-activatable fibrinolysis inhibitor levels and Thr325Ile polymorphism as a risk marker of myocardial infarction in Egyptian patients. Acta Cardiol. 2011;66:483–8.PubMed

29.

Saghafi H, Mahmoodi MJ, Fakhrzadeh H, Heshmat R, Shafaee A, Larijani B. Cardiovascular risk factors in first-degree relatives of patients with premature coronary artery disease. Acta Cardiol. 2006;61(6):607–13.PubMedCrossRef

30.

Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–47.PubMedCrossRef

31.

Sheridan SL, Viera AJ, Krantz MJ, Ice CL, Steinman LE, Peters KE, et al. The effect of giving global coronary risk information to adults: a systematic review. Arch Intern Med. 2010;170:230–9.PubMedCrossRef

32.

Janssens ACJ, Ioannidis JP, van Duijn CM, Little J, Khoury MJ. Strengthening the reporting of genetic risk prediction studies: the GRIPS statement. Genome Med. 2011;3:16.PubMedPubMedCentralCrossRef

33.

Schussler JM. Effectiveness and safety of transradial artery access for cardiac catheterization. Proc (Bayl Univ Med Cent). 2011;24:205–9.

34.

Saha T, Khalequzzaman M, Akanda A-k, Saha S, Tushar AZ, Ahmed R, et al. Association of GRACE risk score with angiographic severity of coronary artery disease in patients with ST elevation myocardial infarction. Cardiovasc J. 2015;8:30–4.CrossRef

35.

Scognamiglio R, Negut C, Ramondo A, Tiengo A, Avogaro A. Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus. J Am Coll Cardiol. 2006;47:65–71.PubMedCrossRef

36.

Gökdeniz T, Kalaycıoğlu E, Aykan AÇ, Boyacı F, Turan T, Gü İ, et al. Value of coronary artery calcium score to predict severity or complexity of coronary artery disease. Arq Bras Cardiol. 2014;102:120–7.PubMedPubMedCentral

37.

Khandelwal G, Jain A, Rathore M. Prediction of angiographic extent of coronary artery disease on the basis of clinical risk scores in patients of unstable angina. J Clin Diagn Res. 2015;9:OC13–6.PubMedPubMedCentral

38.

Özdemir B, Emül A, Özdemir L, Sağ S, Biçer M, Aydınlar A. Association of aortic diameters with coronary artery disease severity and albumin excretion. Biomed Res Int. 2015;2015:857628.PubMedPubMedCentralCrossRef

39.

Onaka L. Lipids. In: Anderson SC, Cockayne S, editors. Clinical chemistry: concepts and applications. London: WB Saunders; 1993. p. 166–83.

40.

Kotze MJ, Kriegshäuser G, Thiart R, de Villiers NJ, Scholtz CL, Kury F, et al. Simultaneous detection of multiple familial hypercholesterolemia mutations facilitates an improved diagnostic service in South African patients at high risk of cardiovascular disease. Mol Diagn. 2003;7:169–74.PubMedCrossRef

41.

Strip assay evaluator Web-edition, Release 2 (version 2.10). http://viennalab.sci-design.at/webevaluator/. Accessed 14 Oct 2016.

42.

Online Encyclopedia for Genetic Epidemiology studies (OEGE). Hardy-Weinberg equilibrium calculator including analysis for ascertainment bias. http://www.oege.org/software/hardy-weinberg.html. Accessed 14 Oct 2016.

43.

Fawzy MS, Hussein MH, Abdelaziz EZ, Yamany HA, Ismail HM, Toraih EA. Association of MicroRNA-196a2 variant with response to short-acting β2-agonist in COPD: an Egyptian pilot study. PLoS One. 2016;11:e0152834.PubMedPubMedCentralCrossRef

44.

McCune B, Mefford MJPC-ORD. Multivariate analysis of ecological data, version 5.0 for windows. 2006.

45.

Roberts R, Stewart AF, Wells GA, Williams KA, Kavaslar N, McPherson R. Identifying genes for coronary artery disease: an idea whose time has come. Can J Cardiol. 2007;23:7A–15A.PubMedPubMedCentralCrossRef

46.

Shaker O, Fayez S, Zarouk W, Shehata M. Fibrinogen b-455 G/A and prothrombin 20210 G/A polymorphisms and coronary heart disease: an Egyptian case–control study. Med Rese J. 2011;10:102–9.CrossRef

47.

Dai X, Wiernek S, Evans JP, Runge MS. Genetics of coronary artery disease and myocardial infarction. World J Cardiol. 2016;8:1–23.PubMedPubMedCentralCrossRef

48.

Butt C, Zheng H, Randell E, Robb D, Parfrey P. Combined carrier status of prothrombin 20210A and factor XIII-A Leu34 alleles as a strong risk factor for myocardial infarction: evidence of a gene-gene interaction. Blood. 2003;101:3037–41.PubMedCrossRef

49.

Zaatari GS, Otrock ZK, Sabbagh AS, Mahfouz RA. Prevalence of factor V R2 (H1299R) polymorphism in the Lebanese population. Pathology. 2006;38:442–4.PubMedCrossRef

50.

Segers K, Dahlbäck B, Nicolaes GA. Coagulation factor V and thrombophilia: background and mechanisms. Thromb Haemost. 2007;98:530–42.PubMed

51.

Martinelli I. Risk factors in venous thromboembolism. Thromb Haemost. 2001;86:395–403.PubMed

52.

Trifonova EA, Spiridonova MG, Stepanov VA. Genetic diversity and the structure of linkage disequilibrium in the methylenetetrahydrofolate reductase locus. Genetika. 2008;44:1410–9.PubMed

53.

Tajouri L, Martin V, Gasparini C, Ovcaric M, Curtain R, Lea RA, et al. Genetic investigation of methylenetetrahydrofolate reductase (MTHFR) and catechol-O-methyl transferase (COMT) in multiple sclerosis. Brain Res Bull. 2006;69:327–31.PubMedCrossRef

54.

Heidari MM, Khatami M, Hadadzadeh M, Kazemi M, Mahamed S, Malekzadeh P, et al. Polymorphisms in NOS3, MTHFR APOB and TNF-α Genes and Risk of Coronary Atherosclerotic Lesions in Iranian Patients. Res Cardiovasc Med. 2015;5:e29134.PubMedPubMedCentralCrossRef

55.

Almawi WY, Ameen G, Tamim H, Finan RR, Irani-Hakime N. Factor V G1691A, prothrombin G20210A, and methylenetetrahydrofolate reductase (MTHFR]) C677T gene polymorphism in angiographically documented coronary artery disease. J Thromb Thrombolysis. 2004;17:199–205.PubMedCrossRef

56.

Neto AI, Moura Jr JR, Persuhn DC. Frequency of MTHFR G1793A polymorphism in individuals with early coronary artery disease: cross-sectional study. Sao Paulo Med J. 2013;131:296–300.PubMedCrossRef

57.

Yamada Y, Matsuo H, Segawa T, Watanabe S, Kato K, Hibino T, et al. Assessment of genetic risk for myocardial infarction. Thromb Haemost. 2006;96:220–7.PubMed

58.

Schürks M, Zee RY, Buring JE, Kurth T. Interrelationships among the MTHFR 677C > T polymorphism, migraine, and cardiovascular disease. Neurology. 2008;71:505–13.PubMedPubMedCentralCrossRef

59.

Hsu LA, Ko YL, Wang SM, Chang CJ, Hsu TS, Chiang CW, et al. The C677T mutation of the methylene tetrahydrofolate reductase gene is not associated with the risk of coronary artery disease or venous thrombosis among Chinese in Taiwan. Hum Hered. 2001;51:41–5.PubMedCrossRef

60.

Yilmaz H, Agachan B, Ergen A, Karaalib ZE, Isbir T. Methylene tetrahydrofolate reductase C677T mutation and left ventricular hypertrophy in Turkish patients with type II diabetes mellitus. J Biochem Mol Biol. 2004;37:234–8.PubMed

61.

Caner M, Bircan R, Sevinç D, Benli F, Güney AI, Kurtoglu N. MTHFR, prothrombin and Factor V gene variants in Turkish patients with coronary artery stenosis. Genet Mol Biol. 2008;31:836–8.CrossRef

62.

Pepper MS. Role of the matrix metalloproteinase and plasminogen activator plasmin systems in angiogenesis. Arterioscler Thromb Va-sc Biol. 2001;21:1104–17.CrossRef

63.

Mehta R, Shapiro A. Plasminogen activator inhibitor type 1 deficiency. Haemophilia. 2008;14:1255–60.PubMedCrossRef

64.

Collet JP, Montalescot G, Vicaut E, Ankri A, Walylo F, Lesty C, et al. Acute release of plasminogen activator inhibitor-1 in ST segment elevation myocardial infarction predicts mortality. Circulation. 2003;108:391–4.PubMedCrossRef

65.

Ding J, Nicklas BJ, Fallin MD, de Rekeneire N, Kritchevsky SB, Pahor M, et al. Plasminogen activator inhibitor type 1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but not with myocardial infarction or stroke. Am Heart J. 2006;152:1109–15.PubMedCrossRef

66.

Li Y, Di C, Li W, Cai W, Tan X, Xu L, et al. Oncomirs miRNA-221/222 and tumor suppressors miRNA-199a/195 Are crucial miRNAs in liver cancer: a systematic analysis. Dig Dis Sci. 2016;61:2315–27.PubMedPubMedCentralCrossRef

67.

Zhang H, Dong P, Yang X, Liu Z. Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with coronary artery disease risk: a meta-analysis. Int J Clin Exp Med. 2014;7:3777–88.PubMedPubMedCentral

68.

Tsantes AE, Nikolopoulos GK, Bagos PG, Bonovas S, Kopterides P, Vaiopoulos G. The effect of the plasminogen activator inhibitor-1 4G/5G gene polymorphism on the thrombotic risk. Thromb Res. 2008;122:736–42.PubMedCrossRef

69.

Ismail S, Abdel Azeem AA, Abdel Hamid MA, Nowier SR, Morad H. The role of 4G/5G genetic polymorphism of plasminogen activator inhibitor-1 gene in myocardial infarction among Egyptians. Life Sci J. 2011;8:32–9.

70.

Anderson JL, Muhlestein JB, Habashi J, Carlquist JF, Bair TL, Elmer SP, et al. Lack of association of a common polymorphism of the plasminogen activator inhibitor-1 gene with coronary artery disease and myocardial infarction. J Am Coll Cardiol. 1999;34:1778–83.PubMedCrossRef

71.

Crainich P, Jenny NS, Tang Z, Arnold AM, Kuller LH, Manolio T, et al. Lack of association of the plasminogen activator inhibitor-1 4G/5G promoter polymorphism with cardiovascular disease in the elderly. J Thromb Haemost. 2003;1:1799–804.PubMedCrossRef

72.

Mertens I, Verrijken A, Michiels JJ, Van der Planken M, Ruige JB, Van Gaal LF. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes (Lond). 2006;30:1308–14.CrossRef

73.

Alessi M-C, Poggi M, Juhan-Vague I. Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. Curr Opin Lipidol. 2007;18:240–5.PubMedCrossRef

74.

Fernandes KS, Sandrim VC. 4G/5G polymorphism modulates PAI-1 circulating levels in obese women. Mol Cell Biochem. 2012;364:299–301.PubMedCrossRef

75.

Margaglione M, Cappucci G, Colaizzo D, Giuliani N, Vecchione G, Grandone E, et al. The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease. Arterioscler Thromb Vasc Biol. 1998;18:152–6.PubMedCrossRef

76.

Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb. 1991;11:183–90.PubMedCrossRef

77.

Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost. 1995;74:837–41.PubMed

78.

Nordt TK, Lohrmann J, Bode C. Regulation of PAI-1 expression by genetic polymorphism. Impact on atherogenesis. Thromb Res. 2001;103:S1–5.PubMedCrossRef

79.

Eliasson M, Asplund K, Ervin PE, Lundblad D. Relationship of cigarette smoking and snuff dipping to plasma fibrinogen, fibrinolytic variables and serum insulin: the Northern Sweden MONICA study. Atherosclerosis. 1995;113:41–53.PubMedCrossRef

80.

Floyd CN, Ferro A, Warner TD. Expression of the PlA2 allele of glycoprotein IIIa and its impact on platelet function. JRSM Cardiovasc Dis. 2015;4:2048004015610252.PubMedPubMedCentral

81.

Newman PJ, Derbes RS, Aster RH. The human platelet alloantigens, PlA1 and PlA2, are associated with a leucine33/proline33 amino acid polymorphism in membrane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest. 1989;83:1778–81.PubMedPubMedCentralCrossRef

82.

Corral J, González-Conejero R, Rivera J, Iniesta JA, Lozano ML, Vicente V. HPA-1 genotype in arterial thrombosis-role of HPA-1b polymorphism in platelet function. Blood Coagul Fibrinolysis. 1997;8:284–90.PubMedCrossRef

83.

Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med. 1996;334:1090–4.PubMedCrossRef

84.

Abboud N, Amin H, Ghazouani L, Ben Haj Khalifa S, Ben Khalafallah A, Aded F, Almawi WY, Mahjoub T. Polymorphisms of human platelet alloantigens HPA-1 and HPA-2 associated with severe coronary artery disease. Cardiovasc Pathol. 2010;19:302–7.PubMedCrossRef

85.

Bennett JS, Catella-Lawson F, Rut AR, Vilaire G, Qi W, Kapoor SC, et al. Effect of the Pl (A2) alloantigen on the function of beta (3)-integrins in platelets. Blood. 2001;97:3093–9.PubMedCrossRef

86.

Floyd CN, Mustafa A, Ferro A. The PlA1/A2 polymorphism of glycoprotein IIIa as a risk factor for myocardial infarction: a meta-analysis. PLoS One. 2014;9:e101518.PubMedPubMedCentralCrossRef

87.

Floyd CN, Ellis BH, Ferro A. The PlA1/A2 polymorphism of glycoprotein IIIa as a risk factor for stroke: a systematic review and meta-analysis. PLoS One. 2014;9:e100239.PubMedPubMedCentralCrossRef

88.

Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008;336:195–8.PubMedPubMedCentralCrossRef

89.

Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke and venous thrombosis in a large cohort of US men. Circulation. 1999;99:999–1004.PubMedCrossRef

90.

Samani NJ, Lodwick D. Glycoprotein IIIa polymorphism and risk of myocardial infarction. Cardiovasc Res. 1997;33:693–7.PubMedCrossRef

91.

Scaglione L, Bergerone S, Gaschino G, Imazio M, Maccagnani A, Gambino R, et al. Lack of relationship between the P1A1/P1A2 polymorphism of platelet glycoprotein IIIa and premature myocardial infarction. Eur J Clin Invest. 1998;28:385–8.PubMedCrossRef

92.

Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Platelet glycoprotein receptor IIIa polymorphism PLA1/PLA2 and coronary risk: a meta-analysis. Thromb Haemost. 2001;85:626–33.PubMed

93.

Zotz RB, Winkelmann BR, Mu¨ller C, Boehm BO, Ma¨rz W, Scharf RE. Association of polymorphisms of platelet membrane integrins α_IIbβ₃ (HPA-1b/Pl^A2) and α₂β₁ (α₂807TT) with premature myocardial infarction. J Thromb Haemost. 2005;3:1522–9.PubMedCrossRef

94.

Zeinali N, Hashemi M, Mirmohammadsadeghi M, Mirmohammadsadeghi H, Eskandari N, Sabzghabaee AM. Association of angiotensin-converting enzyme genotype, insertion/deletion polymorphism and saphenous vein graft atherosclerosis in Iranian patients. Braz J Cardiovasc Surg. 2015;30:557–61.PubMedPubMedCentral

95.

Demurtas P, Orrù G, Coni P, Minerba L, Corrias M, Sirigu P, et al. Association between the ACE insertion/deletion polymorphism and pterygium in Sardinian patients: a population based case–control study. BMJ Open. 2014;4:e005627.PubMedPubMedCentralCrossRef

96.

Cambien F, Poirer O, Lecerf L, Evans A, Cambou J-P, Arveiler D, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359:641–4.PubMedCrossRef

97.

Morris BJ. Hypothesis: an angiotensin converting enzyme genotype present in one in three Caucasians, is associated with increased mortality rate. Clin Exp Pharmacol Physiol. 1996;23:1–10.PubMedCrossRef

98.

Oike Y, Hata A, Ogata Y, Numata Y, Shido K, Kondo K. Angiotensin converting enzyme as a genetic risk factor for coronary artery spasm: implication in the pathogenesis of myocardial infarction. J Clin Invest. 1995;96:2975–9.PubMedPubMedCentralCrossRef

99.

Ohishi M, Fujii K, Minamino T, Hagaki J, Kamitani A, Rakugi H, et al. A potent genetic risk factor for restenosis. (Letter). Nature Genet. 1993;5:324–5.PubMedCrossRef

100.

Samani NJ, Thompson JR, O’Toole L, Channer K, Woods KL. A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation. 1996;94:708–12.PubMedCrossRef

101.

Zhou L, Xi B, Wei Y, Shen W, Li Y. Meta-analysis of the association between the insertion/deletion polymorphism in ACE gene and coronary heart disease among the Chinese population. J Renin Angiotensin Aldosterone Syst. 2012;13:296–304.PubMedCrossRef

102.

Higaki J, Baba S, Katsuya T, Sato N, Ishikawa K, Mannami T, et al. Deletion allele of angiotensin-converting enzyme gene increases risk of essential hypertension in Japanese men: the Suita Study. Circulation. 2000;101:2060–5.PubMedCrossRef

103.

Butler R, Morris AD, Struthers AD. Angiotensin-converting enzyme gene polymorphism and cardiovascular disease. Clin Sci. 1997;93:391–400.PubMedCrossRef

104.

Bashyam MD, Savithri GR, Kumar MS, Narasimhan C, Nallari P. Molecular genetics of familial hypertrophic cardiomyopathy (FHC). J Hum Genet. 2003;48:55–64.PubMedCrossRef

105.

Tseng CH, Tseng FH, Chong CK, Tseng CP, Cheng JC. Angiotensin-converting enzyme genotype and peripheral arterial disease in diabetic patients. Exp Diabetes Res. 2012;2012:698695.PubMed

106.

Zhang Z, Xu G, Liu D, Fan X, Zhu W, Liu X. Angiotensin-converting enzyme insertion/deletion polymorphism contributes to ischemic stroke risk: a meta-analysis of 50 case-control studies. PLoS One. 2012;7:e46495.PubMedPubMedCentralCrossRef

107.

Fatini C, Gensini F, Sticchi E, Battaglini B, Prisco D, Fedi S, et al. ACE DD genotype: an independent predisposition factor to venous thromboembolism. Eur J Clin Invest. 2003;33:642–7.PubMedCrossRef

108.

Lindpaintner K, Pfeffer MA, Kreutz R, Stampfer MJ, Grodstein F, LaMotte F, et al. A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. New Eng J Med. 1995;332:706–11.PubMedCrossRef

109.

Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol. 2009;78:539–52.PubMedPubMedCentralCrossRef

110.

Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86:1343–6.PubMedPubMedCentralCrossRef

111.

Suehiro T, Morita T, Inoue M, Kumon Y, Ikeda Y, Hashimoto K. Increased amount of the angiotensin-converting enzyme (ACE) mRNA originating from the ACE allele with deletion. Hum Genet. 2004;115:91–6.PubMedCrossRef

112.

Shen H, Damcott CM, Rampersaud E, Pollin TI, Horenstein RB, McArdle PF, et al. Familial defective apolipoprotein B-100 and increased low-density lipoprotein cholesterol and coronary artery calcification in the old order amish. Arch Intern Med. 2010;170:1850–5.PubMedPubMedCentralCrossRef

113.

Tybjaerg-Hansen A, Humphries SE. Familial defective apolipoprotein B-100: A single mutation that causes hypercholesterolemia and premature coronary artery disease. Atherosclerosis. 1992;96:91–107.PubMedCrossRef

114.

Tybjaerg-Hansen A, Steffensen R, Meinertz H, Schnohr P, Nordestgaard BG. Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. N Engl J Med. 1998;338:1577–84.PubMedCrossRef

115.

Ludwig EH, Hopkins PN, Allen A, Wu LL, Williams RR, Anderson JL, et al. Association of genetic variations in apolipoprotein B with hypercholesterolemia, coronary artery disease, and receptor binding of low density lipoproteins. J Lipid Res. 1997;38:1361–73.PubMed

116.

Borén J, Lee I, Zhu W, Arnold K, Taylor S, Innerarity TL. Identification of the low density lipoprotein receptor-binding site in apolipoprotein B100 and the modulation of its binding activity by the carboxyl terminus in familial defective apo-B100. J Clin Invest. 1998;101:1084–93.PubMedPubMedCentralCrossRef

117.

Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol. 2004;160:407–20.PubMedCrossRef

118.

Sabbagh AS, Daher RT, Otrock ZK, Khalek RN, Zaatari GS, Mahfouz RA. ApoB-100 R3500Q mutation in the Lebanese population: prevalence and historical review of the literature. Mol Biol Rep. 2007;34:267–70.PubMedCrossRef

119.

Zakharova FM, Damgaard D, Mandelshtam MY, Golubkov VI, Nissen PH, Nilsen GG, et al. Familial hypercholesterolemia in St-Petersburg: the known and novel mutations found in the low density lipoprotein receptor gene in Russia. BMC Med Genet. 2005;6:6.PubMedPubMedCentralCrossRef

120.

Sözen MM, Whittall R, Oner C, Tokatli A, Kalkanoğlu HS, Dursun A, et al. The molecular basis of familial hypercholesterolaemia in Turkish patients. Atherosclerosis. 2005;180:63–71.PubMedCrossRef

121.

Wang YL, Sun LM, Zhang L, Xu HT, Dong Z, Wang LQ, et al. Association between apolipoprotein E polymorphism and myocardial infarction risk: a systematic review and meta-analysis. FEBS Open Bio. 2015;5:852–8.PubMedPubMedCentralCrossRef

122.

Ghebranious N, Ivacic L, Mallum J, Dokken C. Detection of ApoE E2, E3 and E4 alleles using MALDI-TOF mass spectrometry and the homogeneous mass-extend technology. Nucleic Acids Res. 2005;33:e149.PubMedPubMedCentralCrossRef

123.

McNeill E, Channon KM, Greaves DR. Inflammatory cell recruitment in cardiovascular disease: murine models and potential clinical applications. Clin Sci. 2010;118:641–55.PubMedCrossRef

124.

Eichner JE, Kuller LH, Orchard TJ, Grandits GA, McCallum LM, Ferrell RE, et al. Relation of apolipoprotein E phenotype to myocardial infarction and mortality from coronary artery disease. Am J Cardiol. 1993;71:160–5.PubMedCrossRef

125.

Ventakaramana P, Reddy C, Ferrell RE. Apolipoprotein E polymorphism in two populations of Andhra Pradesh. Ind J Hum Genet. 1999;5:31–5.

126.

Hergenc G, Taga Y, Emerk K, Cirakoglu B. Apolipoprotein E genotyping in Turkish myocardial infarction survivors and healthy controls. J Biomed Sci. 1995;2:46–9.PubMedCrossRef

127.

Dzimiri N, Meyer BF, Hussain SS, Basco C, Afrane B, Halees Z. Relevance of apolipoprotein E polymorphism for coronary artery disease in the Saudi population. Arch Pathol Lab Med. 1999;123:1241–5.PubMed

128.

Lenzen HJ, Assmann G, Buchwalsky R, Schulte H. Association of apolipoprotein E polymorphism, low-density lipoprotein cholesterol, and coronary artery disease. Clin Chem. 1986;32:778–81.PubMed

129.

Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240:622–30.PubMedCrossRef

130.

McCarron MO, Delong D, Alberts MJ. APOE genotype as a risk factor for ischemic cerebrovascular disease: a meta-analysis. Neurology. 1999;53:1308–11.PubMedCrossRef

131.

Liu S, Song Y, Hu FB, Niu T, Ma J, Gaziano M, Stampfer MJ. A prospective study of the APOA1 XmnI and APOC3 SstI polymorphisms in the APOA1/C3/A4 gene cluster and risk of incident myocardial infarction in men. Atherosclerosis. 2004;177:119–26.PubMedCrossRef

132.

Xu H, Li H, Liu J, Zhu D, Wang Z, Chen A, Zhao Q. Meta-analysis of apolipoprotein E gene polymorphism and susceptibility of myocardial infarction. PLoS One. 2014;9:e104608.PubMedPubMedCentralCrossRef

133.

Zhang Y, Tang HQ, Peng WJ, Zhang BB, Liu M. Meta-analysis for the Association of Apolipoprotein E ε2/ε3/ε4 Polymorphism with Coronary Heart Disease. Chin Med J (Engl). 2015;128:1391–8.CrossRef

134.

Mahley RW, Rall Jr SC. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507–37.PubMedCrossRef

135.

Jiang L, Zhong J, Dou X, Cheng C, Huang Z, Sun X. Effects of ApoE on intracellular calcium levels and apoptosis of neurons after mechanical injury”. Neuroscience. 2015;301:375–83.PubMedCrossRef

Title: Atherosclerotic and thrombotic genetic and environmental determinants in Egyptian coronary artery disease patients: a pilot study
Authors: Manal S. Fawzy
Eman A. Toraih
Nagwa M. Aly
Abeer Fakhr-Eldeen
Dahlia I. Badran
Mohammad H. Hussein
Publication date: 01-12-2017
Publisher: BioMed Central
Published in: BMC Cardiovascular Disorders / Issue 1/2017
Electronic ISSN: 1471-2261
DOI: https://doi.org/10.1186/s12872-016-0456-3

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Home
Congress Coverage
Clinical Collections
- Advances in Alzheimer’s
About Springer Medicine
Key Specialties